EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Glycyrrhizin preparations in liver diseases: a narrative review of mechanisms and therapeutic potential

Tianyu Ma, Hongxiao Hao, Shuojie Wang, Dianya Qiu, Weihua Cao, Wen Deng, Shiyu Wang, Xinxin Li, Ziyu Zhang, Xin Wei, Linmei Yao, Zixuan Gao und 3 weitere

Frontiers in Pharmacology · 30.04.2026 · 17

DOI: 10.3389/fphar.2026.1795174 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.04.2026. Verfasst von Tianyu Ma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glycyrrhizin preparations (GLPS), derived from Glycyrrhiza uralensis (licorice), are widely used hepatoprotective agents in clinical practice. Their primary active components, 18α- and 18β-glycyrrhetinic acid (GA), are represented by formulations including diammonium glycyrrhizinate (DG), compound glycyrrhizin (CG), and magnesium isoglycyrrhizinate (MgIG). This review provides a comprehensive overview of the pharmacokinetic properties of GLPS and their multi-target pharmacological mechanisms, comprising anti-inflammatory, membrane-stabilizing, antioxidant, anti-apoptotic, immunomodulatory, and anti-fibrotic effects that collectively underpin their hepatoprotective activity. We critically evaluate clinical evidence across major liver diseases, including viral hepatitis, drug-induced liver injury, alcoholic liver disease, non-alcoholic fatty liver disease, and autoimmune hepatitis, while highlighting heterogeneity in study designs, geographical concentration of evidence, and the predominance of positive findings that may reflect publication bias. Safety considerations, particularly the risk of pseudoaldosteronism and potential drug interactions, are also discussed. Finally, we outline future research directions, emphasizing the need for large-scale, multicenter randomized controlled trials with standardized outcomes to establish more robust evidence base and support broader international clinical adoption.

Schlagwörter

Stichwörter der Autor:innen

clinical applicationsglycyrrhizinglycyrrhizin preparationsliver diseasepharmacological mechanismssafety

Autor:innen und Institutionen

  • Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
  • Department of Gynecology and Obstetrics, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing, China.

Zitieren

APA

Ma, T., Hao, H., Wang, S., Qiu, D., Cao, W., Deng, W., Wang, S., Li, X., Zhang, Z., Wei, X., Yao, L., Gao, Z., Yi, W., Liu, R., & Li, M. (2026). Glycyrrhizin preparations in liver diseases: a narrative review of mechanisms and therapeutic potential. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1795174

Vancouver

Ma T, Hao H, Wang S, Qiu D, Cao W, Deng W, et al. Glycyrrhizin preparations in liver diseases: a narrative review of mechanisms and therapeutic potential. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1795174

BibTeX
@article{Ma2026,
  author = {Ma, Tianyu and Hao, Hongxiao and Wang, Shuojie and Qiu, Dianya and Cao, Weihua and Deng, Wen and Wang, Shiyu and Li, Xinxin and Zhang, Ziyu and Wei, Xin and Yao, Linmei and Gao, Zixuan and Yi, Wei and Liu, Ruyu and Li, Minghui},
  title = {Glycyrrhizin preparations in liver diseases: a narrative review of mechanisms and therapeutic potential},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1795174}
}
Kostenlos starten →